Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF. Medicherla S, et al. Among authors: mangadu r. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. doi: 10.1124/jpet.105.097857. Epub 2006 Apr 7. J Pharmacol Exp Ther. 2006. PMID: 16603672
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. Medicherla S, et al. Among authors: mangadu r. J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. doi: 10.1124/jpet.105.098020. Epub 2006 Apr 5. J Pharmacol Exp Ther. 2006. PMID: 16597712
p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.
Medicherla S, Wadsworth S, Cullen B, Silcock D, Ma JY, Mangadu R, Kerr I, Chakravarty S, Luedtke GL, Dugar S, Protter AA, Higgins LS. Medicherla S, et al. Among authors: mangadu r. Diabetes Metab Syndr Obes. 2009 Jun 23;2:91-100. Diabetes Metab Syndr Obes. 2009. PMID: 21437122 Free PMC article.
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Uhl M, et al. Among authors: mangadu r. Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013. Cancer Res. 2004. PMID: 15520202
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S, Wilson DC, Yu Y, Wong J, Naravula S, Ermakov G, Riener R, Bhagwat B, Necheva AS, Grein J, Churakova T, Mangadu R, Georgiev P, Manfra D, Pinheiro EM, Sriram V, Bailey WJ, Herzyk D, McClanahan TK, Willingham A, Beebe AM, Sadekova S. Sukumar S, et al. Among authors: mangadu r. Cancer Res. 2017 Aug 15;77(16):4378-4388. doi: 10.1158/0008-5472.CAN-16-1439. Epub 2017 Jun 13. Cancer Res. 2017. PMID: 28611044
Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.
Chan IH, Jain R, Tessmer MS, Gorman D, Mangadu R, Sathe M, Vives F, Moon C, Penaflor E, Turner S, Ayanoglu G, Chang C, Basham B, Mumm JB, Pierce RH, Yearley JH, McClanahan TK, Phillips JH, Cua DJ, Bowman EP, Kastelein RA, LaFace D. Chan IH, et al. Among authors: mangadu r. Mucosal Immunol. 2014 Jul;7(4):842-56. doi: 10.1038/mi.2013.101. Epub 2013 Nov 27. Mucosal Immunol. 2014. PMID: 24280935 Free article.
13 results